[{"orgOrder":0,"company":"PentixaPharm","sponsor":"ELSA Eckert Life Science Accelerator","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Series A Financing","leadProduct":"Pentixafor","moa":"CXCR4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"PentixaPharm","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"PentixaPharm \/ ELSA Eckert Life Science Accelerator","highestDevelopmentStatusID":"6","companyTruncated":"PentixaPharm \/ ELSA Eckert Life Science Accelerator"}]

Find Clinical Drug Pipeline Developments & Deals for Pentixafor

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PentixaPharm

                          Country arrow
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          PentixaPharm

                          Country arrow
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Funding is dedicated for a phase II trial of the imaging compound PentixaFor and for a phase I trial of the therapeutic compound PentixaTher in Central Nervous System Lymphoma.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          February 06, 2020

                          Lead Product(s) : Pentixafor

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : ELSA Eckert Life Science Accelerator

                          Deal Size : $16.2 million

                          Deal Type : Series A Financing

                          blank